Shares of Sagent Pharmaceuticals Inc. (NASDAQ:SGNT) saw an uptick in trading volume on Friday . 2,251,106 shares changed hands during mid-day trading, an increase of 187% from the previous session’s volume of 785,150 shares.The stock last traded at $21.73 and had previously closed at $21.73.

A number of research firms have weighed in on SGNT. Royal Bank Of Canada restated an “outperform” rating and issued a $20.00 price target (down from $28.00) on shares of Sagent Pharmaceuticals in a research note on Wednesday, May 4th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $22.00 target price (down from $23.00) on shares of Sagent Pharmaceuticals in a research note on Wednesday, May 4th. JPMorgan Chase & Co. reiterated a “hold” rating and set a $18.00 target price on shares of Sagent Pharmaceuticals in a research note on Wednesday, May 4th. Zacks Investment Research downgraded Sagent Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, June 10th. Finally, Jefferies Group reiterated a “hold” rating and set a $15.00 target price (up from $13.00) on shares of Sagent Pharmaceuticals in a research note on Friday, June 17th. Eight investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $18.54.

The stock’s 50 day moving average is $21.54 and its 200-day moving average is $15.29. The stock’s market capitalization is $715.13 million.

Sagent Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.